A multicenter, Phase II trial of weekly irinotecan (CPT‐11) in patients with previously treated colorectal carcinoma

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Cancer

• Publication date

  1999-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/(SICI)1097-0142(19990215)85:4<786::AID-CNCR5>3.0.CO;2-9PMID 10091755
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.

  2000cited by this paper
• Cancer statistics, 1997

  1997cited by this paper
• Topoisomerase I inhibitors: review and update.

  1997cited by this paper
• Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.

  1997cited by this paper
• Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

  1997cited by this paper
• Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.

  1996cited by this paper
• CPT-11: an original spectrum of clinical activity.

  1996cited by this paper
• Promising new agents in oncologic treatment.

  1996cited by this paper
• Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.

  1996cited by this paper
• Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

  1996cited by this paper
• Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.

  1996cited by this paper
• Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.

  1995cited by this paper
• Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea.

  1994cited by this paper
• Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.

  1994cited by this paper
• Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

  1994cited by this paper
• Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.

  1994cited by this paper
• Mechanisms of topoisomerase I inhibition by anticancer drugs.

  1994cited by this paper
• Phase I and pharmacokinetic trial of weekly CPT-11.

  1993cited by this paper
• The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.

  1993cited by this paper
• CPT-11-induced cholinergic effects in cancer patients.

  1993cited by this paper
• Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

  1993cited by this paper
• DNA Damage and Cell Killing by Camptothecin and Its Derivative in Human Leukemia HL‐60 Cells

  1993cited by this paper
• Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project.

  1992cited by this paper
• [Conversion of CPT-11 into SN-38 in human tissues].

  1991cited by this paper
• Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.

  1991cited by this paper
• Significance of a fall in serum CEA concentration in patients treated with cytotoxic chemotherapy for disseminated colorectal cancer.

  1987cited by this paper
• Carcinoembryonic antigen (CEA) as a monitor of chemotherapy in disseminated colorectal cancer

  1978cited by this paper
• Serial plasma carcinoembryonic antigen measurements in the management of metastatic colorectal carcinoma.

  1978cited by this paper

• Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management

  2025cites this paper
• Liposomal Vardenafil and Linagliptin Combined with Irinotecan for Synergistic Colorectal Cancer Therapy

  2025cites this paper
• Impact of Omega 3 on the Genotoxicity of Irinotecan on Bone Marrow and Spleen of Rats: in-vivo Study

  2023cites this paper
• Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy for Refractory Colorectal Liver Metastasis: A Systematic Review

  2023cites this paper
• Incidence and non-genetic risk factors of irinotecan-induced severe neutropenia in Chinese adult inpatients

  2023cites this paper
• Covalent CES2 Inhibitors Protect against Reduced Formation of Intestinal Organoids by the Anticancer Drug Irinotecan.

  2022cites this paper
• Systemic Therapy of Common Tumours in Older Patients: Challenges and Opportunities. A Young International Society of Geriatric Oncology Review Paper

  2020cites this paper
• Geriatrische Nephro-Onkologie

  2020cites this paper
• Principles of Chemotherapy in Older Adults

  2019cites this paper
• Carcinoembryonic antigen reduction after medical treatment in patients with metastatic colorectal cancer: a systematic review and meta-analysis

  2019cites this paper
• Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy

  2018cites this paper
• Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.

  2018cites this paper
• Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients

  2018cites this paper
• Impact of diet on irinotecan toxicity in mice.

  2018cites this paper
• Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer

  2017cites this paper
• Patterns of practice with third-line anti-EGFR antibody for metastatic colorectal cancer.

  2016cites this paper
• Different schedules of irinotecan administration: A meta-analysis.

  2016cites this paper
• Efficacy and Toxicity of Hepatic Intra-Arterial Drug-Eluting (Irinotecan) Bead (DEBIRI) Therapy in Irinotecan-Refractory Unresectable Colorectal Liver Metastases

  2016cites this paper
• Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.

  2016cites this paper
• Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.

  2015cites this paper
• Development of a pipeline and protocols for next generation sequencing of blood and formalin-fixed, paraffin-embedded tumour DNA samples

  2015cites this paper
• Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer

  2015cites this paper
• Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.

  2015cites this paper
• TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer

  2015cites this paper
• Bevacizumab in elderly patients with metastatic colorectal cancer.

  2014cites this paper
• Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

  2014influential citation
• An update on the management of metastatic colorectal cancer in the elderly

  2014cites this paper
• The Efficacy of Additional Bevacizumab to Cytotoxic Chemotherapy Regimens for the Treatment of Colorectal Cancer: An Updated Meta-Analysis for Randomized Trials

  2013cites this paper
• Impact of the Physiological Effects of Aging on the Pharmacokinetics and Pharmacodynamics of Systemic Lung Cancer Treatment

  2013cites this paper
• Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer

  2013cites this paper
• Treatment of Colorectal Cancer Using a Combination of Liposomal Irinotecan (Irinophore C™) and 5-Fluorouracil

  2013cites this paper
• Colorectal cancer in elderly patients: from best supportive care to cure.

  2013cites this paper
• Pharmacology of aging and cancer: how useful are pharmacokinetic tests?.

  2013cites this paper
• Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy.

  2012cites this paper
• Raltitrexed + irinotecan as second-line chemotherapy in elderly patients with advanced colorectal cancer

  2012cites this paper
• Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.

  2012cites this paper
• Bevacizumab: overview of the literature

  2012cites this paper
• A Multicenter, Phase I, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Etirinotecan Pegol in Patients with Refractory Solid Tumors

  2012cites this paper
• CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

  2012influential citation
• Bevacizumab: overview of the

  2012cites this paper
• Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: Study of their clinical significance.

  2011cites this paper
• Topoisomerase I Inhibitors – The Camptothecins

  2011cites this paper
• Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].

  2011cites this paper
• Assimilating Oxaliplatin (Eloxatin) into the Management of Colorectal Cancer

  2011cites this paper
• Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for advanced and/or metastatic colorectal cancer

  2010cites this paper
• Anti-epidermal growth factor receptor (EGFR) monoclonal antibody and DNA topoisomerase inhibitor reduce growth of salivary adenoid cystic carcinoma in a murine model

  2010cites this paper
• Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer

  2010cites this paper
• Efficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer

  2010cites this paper
• Antitumor efficacy of colon-specific HPMA copolymer/9-aminocamptothecin conjugates in mice bearing human-colon carcinoma xenografts.

  2009cites this paper
• Comparing safety and efficacy of first‐line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer

  2009cites this paper
• Percutaneous radiofrequency ablation for unresectable colorectal liver metastases: time for shadows to disperse.

  2009cites this paper
• Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy.

  2009cites this paper
• Irinotecan therapy and molecular targets in colorectal cancer: a systemic review.

  2009influential citation
• Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.

  2009cites this paper
• Therapeutic management of colorectal cancer in elderly patients: an update

  2009cites this paper
• A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer

  2009cites this paper
• Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.

  2009cites this paper
• USE OF PHY906 AS TREATMENT FOR INFLAMMATORY BOWEL DISEASE AND/OR IRRITABLE BOWEL SYNDROME

  2009cites this paper
• Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use.

  2009cites this paper
• Chemotherapeutic agents and the skin: An update.

  2008cites this paper
• Salvage radioembolization of liver-dominant metastases with a resin-based microsphere: initial outcomes.

  2008cites this paper
• Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: results from a randomized phase II study.

  2008cites this paper
• Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere

  2008cites this paper
• Role of chemotherapy and novel biological agents in the treatment of elderly patients with colorectal cancer.

  2008cites this paper
• Adjuvant and Palliative Chemotherapy for Colon Cancer in the Elderly Patient

  2008cites this paper
• Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results

  2008cites this paper
• Carcinoembryonic Antigen in Monitoring of Response to Cetuximab plus FOLFIRI or FOLFOX-4 in Patients with Metastatic Colorectal Cancer

  2008influential citation
• Systemic therapy for metastatic colorectal cancer

  2008cites this paper
• Carcinoembryonic antigen in monitoring of response to cetuximab plus FOLFIRI or FOLFOX-4 in patients with metastatic colorectal cancer.

  2008cites this paper
• Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.

  2008cites this paper
• Clinical and pharmacogenetic factors associated with irinotecan toxicity.

  2008cites this paper
• Neoadjuvant chemoradiation for rectal cancer: is more better?

  2008cites this paper
• Irinotecan in the treatment of elderly patients with advanced colorectal cancer.

  2008cites this paper
• A Pilot Human Evaluation of a Formulation of Irinotecan and Hyaluronic Acid in 5-Fluorouracil-Refractory Metastatic Colorectal Cancer Patients

  2008influential citation
• [The RAS paradox of the EGFR-targeted therapy in colorectal cancer].

  2008cites this paper
• International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.

  2007cites this paper
• Green tea polyphenol administration partly ameliorates chemotherapy-induced side effects in the small intestine of mice.

  2007cites this paper
• Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX)

  2007cites this paper
• Metronomic chemotherapy using weekly low-dosage CPT-11 and UFT as postoperative adjuvant therapy in colorectal cancer at high risk to recurrence.

  2007cites this paper
• Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma.

  2007cites this paper
• Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models

  2007cites this paper
• First-Line Treatment Strategies for Elderly Patients with Metastatic Colorectal Cancer

  2007cites this paper
• Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

  2007cites this paper
• Single-Agent Irinotecan for Recurrent/Metastatic Colorectal Cancer: A Retrospective Analysis

  2006cites this paper
• APhase I and Pharmacokinetic Study of Fixed-Dose Selenomethionine and Irinotecan in SolidTumors

  2006cites this paper
• A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients

  2006cites this paper
• A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours.

  2006cites this paper
• Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients.

  2006cites this paper
• A phase I dose-finding clinical pharmacokinetic study of an oral formulation of irinotecan (CPT-11) administered for 5 days every 3 weeks in patients with advanced solid tumours

  2006cites this paper
• Treatment of colorectal cancer in the elderly: a review of the literature.

  2006cites this paper
• Treatment options for colorectal cancer in the elderly

  2006cites this paper
• A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumors.

  2006cites this paper
• Gender aspects of treatment and drug related toxicity in medical oncology

  2006cites this paper
• Single-Agent Irinotecan as Second-Line Weekly Chemotherapy in Elderly Patients with Advanced Colorectal Cancer

  2006cites this paper
• Second-line combination chemotherapy of oral S-1 with cisplatin and irinotecan for colorectal cancer resistant to 5-FU.

  2006cites this paper
• Oxaliplatin and irinotecan: From advanced to adjuvant therapy of colon cancer

  2006cites this paper
• Management of colorectal cancer in older patients.

  2006cites this paper
• Management of liver metastases from colorectal cancer.

  2006cites this paper
• Phase II trial of fortnightly irinotecan (CPT-11) in the treatment of colorectal cancer patients resistant to previous fluoropyrimidine-based chemotherapy

  2005cites this paper
• Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

  2005cites this paper